Interferon-beta increases plasma ceramides of specific chain length in multiple sclerosis patients, unlike fingolimod or natalizumab

Fingolimod is used for the treatment of multiple sclerosis (MS) and targets receptors for the bioactive sphingolipid sphingosine-1-phosphate. Whether fingolimod or other MS therapies conversely affect plasma concentrations of sphingolipids has, however, not yet been analyzed. Herein, we quantified 1...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Florian Ottenlinger, Christoph Alexander Mayer, Nerea Ferreirós, Yannick Schreiber, Anja Schwiebs, Katrin Schmidt, Hanns Ackermann, Josef Pfeilschifter, Heinfried H. Radeke
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2016-11-01
coleção:	Frontiers in Pharmacology
Assuntos:	Ceramides Interferon-beta Multiple Sclerosis Sphingolipids fingolimod natalizumab
Acesso em linha:	http://journal.frontiersin.org/Journal/10.3389/fphar.2016.00412/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!